Overview

A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors

Status:
Unknown status
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
Protocol YY-20394-003 is a phase I single arm, open label study. The primary objective is to assess the safety of YY-20394 in subjects with advanced solid tumor. The secondary objective is to determine the preliminary efficacy and pharmacokinetics (PK).
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai YingLi Pharmaceutical Co. Ltd.